Activity update on therapeutics

Article

The increased activity in ophthalmic research is reflected in the long list of clinical studies in their various stages: nearly 300 studies of various aspects of glaucoma and close to 250 studies on ocular surface, cornea and dry eye.

"The increased activity in ophthalmic research is reflected in the long list of clinical studies in their various stages: nearly 300 studies of various aspects of glaucoma and close to 250 studies on ocular surface, cornea and dry eye. Searching the web for retina clinical studies yields about 250 studies, about 190 studies are listed for macular edema and approximately 70 studies for AMD. This clinical bustle heralds the changes that we will soon see in the practice of ophthalmology," so says Sara Krupsky, one of the organiers of the 8th Symposium on Ocular Pharmacology and Therapeutics (ISOPT) in Rome 3–6 December.

"The landscape of ocular therapeutics cannot be fully portrayed without bringing up innovations in ocular drug delivery such as slow release devices implanted in the eye. ISOPT 2009 will accordingly bring to focus the latest novelties in medical devices," continued Dr Krupsky.

The ISOPT programme is geared to provide a continuum, spreading from basic development of therapeutic concepts to their utilization as drugs and technologies in clinical reality. Considerations common to drug development will be discussed with researchers based in academia, clinical investigators, regulatory affairs and industry professionals.

www.isopt2009.com

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.